All filters
Slidesets
Efficacy and tolerability of grazoprevir and elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV and HIV co-infection: A nonrandomised, open-label clinical trial- Chien-Yu Cheng
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2018
Slidesets
HIV-1/HCV co-infection treatment with single-tablet antiviral regimens (CoSTARs): 12 Weeks of Ledipasvir/ Sofosbuvir (LDV/SOF) after randomized switch to Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (E/C/F/TAF) or rilpivirin- Damian Mccoll
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2018
Slidesets
New indicators for the evaluation of hepatitis B therapy- Xinxin Zhang, MD, PhD
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2018
Slidesets
Sequential cross-section study on hepatitis viruses infection in Chinese AIDS patients- Lin Liu, MD
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2018
Slidesets
Non-alcoholic fatty liver disease in China- Jiangao Fan, MD, PhD
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2018
Slidesets
What is the Virological support for reduced drug regimens?- Josep Llibre, MD, PhD
Presented at:
Spanish HIV Clinical Forum 2018
Slidesets
State of the ART: Integrase Inhibitors Clinical Data- Juan Berenguer, MD
Presented at:
Spanish HIV Clinical Forum 2018
Slidesets
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study- Jésus Troya
Presented at:
Spanish HIV Clinical Forum 2018
Slidesets
Interstitial pneumonia by triple viral co-infection in a CDC C2 HIV- infected patient- Carme Bracke
Presented at:
Spanish HIV Clinical Forum 2018
Slidesets
Clinical Case presentation- Antonio Antela, MD
Presented at:
Spanish HIV Clinical Forum 2018
Slidesets
Integrating novel delivery systems/novel drugs- Maria Luisa Montes, MD, PhD
Presented at:
Spanish HIV Clinical Forum 2018
Slidesets
What is the Pharmacological support for reduced drug regimens?- Esteban Ribera, MD, PhD
Presented at:
Spanish HIV Clinical Forum 2018
Slidesets
HIV integrase Inhibitors: A novel mechanisms of action- Dr. H. Wu
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Resistance Characteristics of different Integrase Inhibitors- Charles Boucher, MD, PhD
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Abstract-driven presentation: Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Treatment-Naïve Asian Adults: Week 144 results- Tina Zheng
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Resistance Characteristics of different Integrase Inhibitors- Charles Boucher, MD, PhD
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Optimal use of integrase inhibitors in routine clinical practice- Kees Brinkman, MD, PhD
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Optimal use of integrase inhibitors in routine clinical practice- Kees Brinkman, MD, PhD
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Abstract-driven presentation: Efficacy and Safety of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir alafenamide (E/C/F/TAF) in Virologically Suppressed Asian Adults with Renal Impairment: 144 Week- Ning Li
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Taiwan’s Experiences with Integrase Inhibitors- Chien-Ching Hung, MD, PhD
Presented at:
Chinese HIV Clinical Forum 2018
Slidesets
Long-term HIV treatment: The Importance of Initial Antiretroviral Regimen Selection- Hongxin Zhao, MD, MPH
Presented at:
Chinese HIV Clinical Forum 2018
Videos
Introduction Session Chair | Asia-Pacific HIV Clinical Forum 2021
Presented at:
Asia-Pacific HIV Clinical Forum 2021
Meeting